Literature DB >> 8971695

Decreased mesopontine choline acetyltransferase levels in schizophrenia. Correlations with cognitive functions.

C N Karson1, R E Mrak, M M Husain, W S Griffin.   

Abstract

The objective was to replicate a reported decrease of choline acetyltransferase (ChAT) in the mesopontine tegmentum of deceased schizophrenics and to see if such a decrease is related to their cognitive status as measured during life. Rigorous antemortem psychiatric evaluations were performed on our large population of schizophrenic patients. Mesopontine tissue was collected promptly following death from eight of these patients, from an additional five schizophrenics without systematic premortem psychiatric evaluation, and from control subjects. ChAT content of this brain tissue was determined using Western immunoblot analysis. There were 13 schizophrenic patients and 8 control subjects. The mean age of subjects in the two groups was similar (64 +/- 9 yr vs 63 +/- 10 yr). Even in the face of reduced post mortem intervals in the patients with schizophrenia, mesopontine tegmental ChAT concentrations were depressed by 70% in schizophrenic patients (1.28 +/- 1.74 vs 4.39 +/- 3.20 ng ChAT/micrograms tissue protein, P < 0.01), and correlated with orientation and reasoning (rs = 0.90 and 0.98, respectively) in those subjects assessed antemortem. Mesopontine ChAT concentrations are depressed in schizophrenia and correlate significantly with measures of cognitive performance in patients with this disorder.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8971695     DOI: 10.1007/BF02815001

Source DB:  PubMed          Journal:  Mol Chem Neuropathol        ISSN: 1044-7393


  10 in total

Review 1.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

2.  Cholinergic blockade under working memory demands encountered by increased rehearsal strategies: evidence from fMRI in healthy subjects.

Authors:  Bianca Voss; Renate Thienel; Martina Reske; Thilo Kellermann; Abigail J Sheldrick; Sarah Halfter; Katrin Radenbach; Nadim J Shah; Ute Habel; Tilo T J Kircher
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-10-18       Impact factor: 5.270

3.  Spatial working memory and the brainstem cholinergic innervation to the anterior thalamus.

Authors:  Anna S Mitchell; John C Dalrymple-Alford; Michael A Christie
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

Review 4.  Abnormal synaptic plasticity and impaired cognition in schizophrenia.

Authors:  Xiu-Lin Wu; Qiu-Jin Yan; Fan Zhu
Journal:  World J Psychiatry       Date:  2022-04-19

5.  Rivastigmine reverses cognitive deficit and acetylcholinesterase activity induced by ketamine in an animal model of schizophrenia.

Authors:  Alexandra I Zugno; Ricardo Filipe Julião; Josiane Budni; Ana Maria Volpato; Daiane B Fraga; Felipe D Pacheco; Pedro F Deroza; Renata D Luca; Mariana B de Oliveira; Alexandra S Heylmann; João Quevedo
Journal:  Metab Brain Dis       Date:  2013-06-19       Impact factor: 3.584

Review 6.  [Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview].

Authors:  B Voss; R Thienel; S Leucht; T Kircher
Journal:  Nervenarzt       Date:  2008-01       Impact factor: 1.214

7.  Cortical neuritic plaques and hippocampal neurofibrillary tangles are related to dementia severity in elderly schizophrenia patients.

Authors:  Michael A Rapp; Michal Schnaider-Beeri; Dushyant P Purohit; Abraham Reichenberg; Susan R McGurk; Vahram Haroutunian; Philip D Harvey
Journal:  Schizophr Res       Date:  2010-01       Impact factor: 4.939

8.  Combining fMRI and SNP data to investigate connections between brain function and genetics using parallel ICA.

Authors:  Jingyu Liu; Godfrey Pearlson; Andreas Windemuth; Gualberto Ruano; Nora I Perrone-Bizzozero; Vince Calhoun
Journal:  Hum Brain Mapp       Date:  2009-01       Impact factor: 5.038

Review 9.  Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What's the Evidence?

Authors:  Wilhelmina A M Vingerhoets; Oswald J N Bloemen; Geor Bakker; Therese A M J van Amelsvoort
Journal:  Front Psychiatry       Date:  2013-12-04       Impact factor: 4.157

10.  Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia.

Authors:  Pattath Narayanan Suresh Kumar; Seema P Mohemmedali; P K Anish; Chittaranjan Andrade
Journal:  Indian J Psychiatry       Date:  2017 Apr-Jun       Impact factor: 1.759

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.